Home Clinical trials For patients Uterus BGOG-EN29/TroFuse-033

BGOG-EN29/TroFuse-033

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer

Open
Trial drug
sac-TMT
Grade
High grade, Low grade, Other / unknown
Prior lines
1
Histology
Endometrioid, Mucinous Serous Clear-cell
Phase
III

Treatment

All participants undergo an initial Induction Phase of six cycles, each cycle consisting of pembrolizumab + carboplatin + paclitaxel or docetaxel. Each cycle is three weeks. Participants  enter the Maintenance Treatment Phase and are then randomly assigned to pembrolizumab + sac-TMT or pembrolizumab monotherapy. 

Treatment duration

A maximum of 14 cycles.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.